Abstract: Connective-tissue-disease-associated pulmonary arterial hypertension (CTD-PAH) is a well-recognised pulmonary complication most commonly seen in patients with systemic sclerosis, followed by systemic lupus erythematosus and mixed connective tissue disease. In systemic-sclerosis-associated-pulmonary arterial hypertension (SSc-PAH), patients usually present late and the progression can be rapid with poor prognosis and survival. Early detection and prompt intervention of SSc-PAH is an important cornerstone to halt the disease progression. Various pulmonary vasodilatory agents were developed over the past two decades. They were shown to improve patients' symptoms, functional status, exercise capacity, haemodynamics and long-term survival. Other immunosuppressive therapies also demonstrated to improve symptoms and functional status in certain group of patients. This article is to review the diagnosis and pharmacological management of patient with CTD-PAH.
particularly in systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and mixed connective tissue disease (MCTD). Connective-tissue-disease-associated pulmonary arterial hypertension (CTD-PAH) is progressive and has poor prognosis (1) . Reported by Condliffe, SSc accounted for 74% of all cases, followed by SLE (8%), MCTD (8%), dermatomyositis/polymyositis (4%), rheumatoid arthritis (3%) and Sjogren (1%) (1) With emerging treatments, patients with PAH have shown marked improvement in symptoms, functional status and survival in the recent years. The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) have published ESC/ERC guidelines for the diagnosis and treatment of pulmonary hypertension, which give new insights on how to manage this group of patients.
Definition and Classification of Pulmonary Hypertension
Pulmonary hypertension (PH) is diagnosed when the mean pulmonary artery pressure (mPAP) is greater than 25 mmHg at rest or 30 mmHg with exercise by right heart catheterisation (2). The severity is based on the value of mPAP and is classified into mild (25-40 mmHg), moderate (41-55 mmHg) and severe (>55 mmHg) (3) . The World Health Organization (WHO) further classified PH into five groups based on the etiologies (Table 1) .
MCTD-PHT is primarily a disease of increased pulmonary vascular resistance caused by proliferation and contraction of pulmonary vascular smooth muscle cells. Other causes of pulmonary hypertension such as chronic lung disease, chronic hypoxia or chronic pulmonary thromboembolism have to be excluded.
WHO further classified PH into four classes based on the functional status (Table 2) .
Introduction Systemic Sclerosis and pulmonary hypertension
Amongst all connective tissue disease, SSc is most associated with CTD-PAH. A meta-analysis of more than 3500 patients with SSc in 2010 demonstrated the prevalence of rheumatological-diseases-related PAH of slightly less than 10% (4). PAH associated with SSc (SSc-PAH) is aggressive, accounting for 30% of mortality in SSc (5) . If left untreated, SSc-PAH is associated with a median survival time of 1 year following diagnosis (6, 7) . The average duration between diagnosis of SSc to the onset of PAH range from 9 to 14 years (8). Patients with SSc-PAH are also susceptible to other organs involvement, for example, renal crisis, left ventricular dysfunction and pericardial effusion (9) . Table 3 summaries the risk factors  for SSc-PAH (Table 3) .
SSc-PAH is further divided into two groups: isolated pulmonary hypertension and PH associated with ILD and they have different clinical characteristics (Table 4) .
Recently, studies demonstrated that nailfold capilloscopy could play a significant role in predicting the development of SSc-PAH. A significantly lower capillary density in nailfold is associated with PH (10,11).
Systemic Lupus Erythematosus and pulmonary hypertension
SLE is the second most common rheumatological condition associated with CTD-PAH. Prevalence of asymptomatic PAH in patients with SLE was reported to be 10.8% (12) , with a female-to-male ratio of 10:1 (13) . It is associated with anti-phospholipid syndrome, anti-RNP Ab, Raynaud's phenomenon and positive rheumatoid factor (14) . Immune-mediated vasculopathy is observed in a small subset of patients with SLE-PAH. They usually accompany with clinical features of pulmonary vasculitis, cutaneous vasculitis and digital gangrene. Patient with SLE-PAH may respond to immunosuppressive therapy. 
Screening of PAH and Echocardiogram
As PAH in SSc is aggressive with poor prognosis, early detection of PAH and prompt initiation of treatments are essential. Data from the French National Registry showed the majority of patients with WHO functional class III or IV were those failed the screening (15) . Echocardiogram remains a most important tool in screening the patient with suspected PH. A peak Tricupsid regurgitation jet velocity (TRJ) >2.9 m/s should raise the suspicious of PH ( Table 5 ).
The ESC/ERC guideline for screening algorithm is based on the peak TJR. In short, a peak TJR of 2.8 m/s or less or sPAP of 36 mHg or less is unlikely to have PH. A peak TJR of greater than 3.4 m/s or an sPAP greater than 45 mmHg is likely to have PH. Along with peak TJR between 2.9 and 3.4 or sPAP between 36 and 45 mmHg, other additional data such as unexplained dyspnoea and other echo findings should be considered to make the clinical judgment (2, 16).
Six-Minute Walk Test and other investigations
The six-minute walk test is a useful tool to evaluate the functional capacity and treatment efficacy in patients with PAH. It is found to predict long-term survival (17) . Early More common in patients with diffuse disease, either as an independent pathological process or as a result of extensive fibrosis Associated with a much worse prognosis 4 Not required literature showed a relationship to 3-year survival using a breakpoint of 332 m. The 3-year survival rate was only 20% if the walk distance was less than 332 m compared to 92% if greater (18) . A more recent analysis of 664 patients with idiopathic PAH from the REVEAL registry found that the 380-m cut-off point had a sensitivity of 79% with a specificity of 55%. The 1-year survival for those patients with six-minute walk distance in excess of 380 m was 98% compared to 89% with lower walk distances (19) .
The six-minute walk distance has been incorporated into treatment guidelines for risk stratification. Patients who are able to walk at least 400 m are at lower risk of mortality and may respond to oral monotherapy. Conversely, patients who are able to walk less than 300 m are at higher risk of mortality and may require more aggressive treatment such as intravenous prostacyclin agonist (PA) or combination therapy.
General management of connective tissue disease-associated pulmonary arterial hypertension
Treatment of CTD-PAH includes non-specific therapies including diuretics, oxygen, anticoagulation and digoxin, and specific drug therapies such as calcium channel blockers, PA, endothelin receptor antagonists (ERA) and phosphodiesterase type-5 inhibitors (PDE5-i) in selected patients. When compared to Group 4 PAH, the use of anticoagulant in idiopathic is associated with a higher bleeding event rate (19 vs 5.4 vs 2.4 event per 100 patient year) but does not improve overall survival. It is not recommended in CTD-PAH according to the ESC/ERC guidelines (20) .
Immunosuppressive treatment for CTD-PAH
Several case series reported the successful outcome of using aggressive immunosuppressive regimen for the treatment of CTD-PAH but general guideline is still lacking. A retrospective series of 23 patients with SLE-PAH or MCTD-PAH treated with monthly intravenous cyclophosphamide and oral prednisolone 0.5-1mg/kg/ day, 50% of patients showed an improvement in WHO functional class, six-minute walk distance and mPAP (21) . Another study of 28 patients with CTD-PAH treated with intravenous cyclophosphamide monotherapy with or without high-dose steroid for at least 3 months, 8 patients (5 SLE-PAH and 3 MCTD-PAH) showed improvement in haemodynamics and functional class but none of the SSc-PAH showed response to immunosuppressive therapy (22) . Improvement is especially marked in those with vasculopathy. Alternatively, azathioprine and mycophenolate mofetil could be used as maintenance treatments (23) . Using high-dose steroid for a short period of time is also found to be effective and led to improvement in functional class (24) .
The PHAROS Cohort is a prospective registry on patients with SSc-PAH. From the cohort, there was a significant survival benefit in patients with SSc-PAH with restrictive lung disease treated with MMF when compared to those without MMF treatment. One-year survival and 3-year survival were 95% vs 80%, and 82% vs 56%, respectively. However, this benefit was not observed in those without restrictive lung disease (25) .
The use of rituximab in PAH lacks evidence. There was a report using the drug in a young patient with SLE with early onset PAH, refractory to multiple treatments subsequently showed significant clinical improvement (26) . More clinical trials are currently going on to explore the role of rituximab in CTD-PAH.
Despite various reported treatment modalities, a Japanese cohort concluded that immunosuppressive therapy does not improve long-term survival and specific treatment with pulmonary vasodilatory agents should be used in combination in the treatment of CTD-PAH (27) .
Vasoreactivity test
Vasoreactivity test is used for suitability of calcium channel blocker (CCB) in group I PHT. The test is positive if the mPAP decreases at least 10 mmHg and to a value less than 40 mmHg, with an increased or unchanged cardiac output, and a minimally reduced or unchanged systemic blood pressure. Positivity predicts beneficial effect of long-term CCB usage.
Specific pulmonary vasodilatory agents
Currently, there are four classes of pulmonary vasodilatory drugs ( 
Prostacyclin Agonist
The PA is the first developed pulmonary vasodilatory agent. Epoprostenol is administered by continuous infusion via a central venous catheter. It was shown to improve symptoms, exercise capacity, haemodynamics (28) and reduce mortality in IPAH (29) . The drug is recommended as the first-line treatment in functional class IV PAH. Treprostinil is an analogue of epoprostenol. It has a longer half-life than epoprostenol and that makes the interruption of the infusion less immediately life threatening. Asides from continuous infusion, it can also be given as subcutaneous injection or inhalation and is considered as an alternative of epoprostenol in class IV PAH (30) . Oral treprostinil failed to improve exercise capacity. (31) . Inhaled iloprost is also shown to improve symptoms and exercise capacity (32) but its frequent administration limits its clinical usage. Continuous intravenous iloprost appears to be as effective as epoprostenol in several case series (33) . Selexipag is another oral prostacyclin agonist reported to reduce morbidity and mortality by 40% (34) .
Endothelin Receptor Antagonist
Bosentan, the first marketed ERA, was developed in 2000. ERA was found to improve haemodymanics, exercise capacities, functional class and time to clinical worsening in RCTs (35) (36) (37) (38) (39) . Liver function derangement is common (up to10%) in patients but appears to be reversible after dose reduction or discontinuation. Ambrisentan was the second oral ERA which shown similar efficacy as Bosentan (40) with lower risk of liver function derangement (0.8-3%). Macitentan was studied in an event-driven RCT with 742 patients with PAH treated with placebo, oral macitentan 3 mg daily and 10 mg daily for 100 weeks. It was shown to reduce mortality and mobility, as well as improvement in exercise capacity. A small portion of patients (4.3%) using 10 mg macitentan showed a reduction of haemoglobin (41) .
Phosphodiesterase-5 inhibitors
Sildenafil was developed in the 2000s and is effective to improve symptoms, exercise capacities, haemodynamics and time to clinical worsening in PAH (42) (43) (44) (45) (46) . Tadalafil was a once-daily dose PDE-5 inhibitor showed similar efficacy as sildenafil (47) . Common side effects include headache, flushing and epitaxis. Nitrate should be avoided in patient taking PDE-5 inhibitors.
Riociguat
Riociguat is a soluble guanylate cyclase stimulant that enhance cGMP production and results in vasodilation. In an RCT of 443 patients with PAH treated with riociguat, improvement in exercise capacities, functional class, haemodynamics were observed with increased time to clinical worsening in patients with and without background therapy (48) .
Combination therapy
Combination therapy with two or three different classes is of peculiar interest in the treatment of PAH recently (Table  7 ) (31, 37, 46, (49) (50) (51) (52) (53) (54) (55) (56) (57) . While combination therapy appears promising in some studies, using riociguat with PDE-5 inhibitors is contraindicated because of hypotension and related deaths detected in an RCT.
Recommendation of use of specific vasodilatory agents
For patients who do not have positive vasoreactive response or improvement despite CCB, the use of specific pulmonary vasodilatory agents is recommended by the WHO functional status of the patient as shown in Table  8 (2, 58). It would be worth to note that specific treatment with pulmonary vasodilatory agents should be initiated early in functional class II patients. Table 7 . Various combination therapy for PAH
Combination therapy Result
Tadalafil plus ambrisentan (AMBITION Trial) (49) One randomised trial of 500 newly diagnosed patients with PAH with WHO functional Class II or III status After 18 months combo treatment, 50% reduction in CHF rate (18% vs 31%) and improvement exercise capacity (49m vs 24 m in six-minute walk) Sildenafil plus bosentan (50, 51, 52) In one prospective cohort, 25 patients showed Improvement in symptoms, exercise capacities, WHO functional class In one study, 33 patients showed improvement in functional class, haemodynamic parameter and survival, independent of aetiology and the order of drug administration In another study of 334 patients with PAH, except for NT-proBNP, adding bosentan to sildenafil therapy was not superior to sildenafil monotherapy in delaying the time to the first morbidity/mortality Sildenafil added to epoprostenol (46) 367 patients with PAH receiving epoprostenol to have sildenafil or placebo for 16 weeks Addition of sildenafil improved haemodynamic parameters, exercise capacities, QOL and time to clinical worsening but no difference in dyspnoea Sildenafil added to iloprost (53) A prospective cohort of 73 patients on long-term inhaled iloprost treatment, 14 fulfilled criteria of deterioration and received 9-to 12-month adjunct oral sildenafil The addition of sildenafil improved exercise capacities, WHO functional class and haemodynamics Bosentan added to epoprostenol (BREATHE-2 trial) (37) 22 patients with PAH on epoprostenol were added bosentan or placebo for 16 weeks Combo therapy improved haemodynamic parameters, exercise capacities and functional class to a greater degree than placebo, though the difference was not statistically significant Bosentan plus iloprost (54, 55) One early observational study suggest that combination was safe and markedly improved exercise capacity in 20 patients A subsequent trial of 40 patients randomly assigned to bosentan alone or bosentan plus iloprost for 12 weeks showed no difference in six-minute walking distance, functional class, peak oxygen uptake and time to clinical worsening Treprostinil added to bosentan or sildenafil (TRIUMPH Trial) (56) 235 patients with PAH, WHO class III or IV, 6 min walk 200-450 m, despite bosentan or sildenafil, were randomly added inhaled treprostinil or placebo for 12 weeks The treprostinil group had a larger improvement in six-minute walking distance and QOL but no difference in the time to clinical worsening, dyspnoea or WHO functional class
Oral treprostinil added to ERA and/ or PDE5-I (the FREEDOM-C and FREEDOM-C2 Study ) (31) FREEDOM-C Study: 354 subjects initially showed significant improvement in dyspnoea fatigue index score, Borg dyspnoea score and combined six-minute walk distance FREEDOM-C2 Study: 310 subjects however later showed no significant improvement in exercise capacities in terms of WHO functional class, Borg dyspnoea score, dyspnoea-fatigue index and clinical symptoms Riociguat added to sildenafil (PATENT PLUS) (57) No favourable effect on haemodynamics and exercise capacity Higher rates of discontinuation dye to hypotension and three deaths (18%) Owing to unfavourable safety profile, FDA issued a warning against combining PDE5-I and Riociguat
Prognosis and monitoring
Prognostic indicators for Group I PH are shown in Table  9 . In general, patients with worsen functional class at the time of diagnosis, rapid progression of heart failure symptoms, a decline in the six-minute walking distance and an echo findings of more worse haemodynamics with high pulmonary and right ventricular (RV) pressure, RV or biventricular dysfunction point to a poor outcome.
Patients with Group I PH should be monitored thrice monthly or even more frequently for clinical symptoms and progression. Ideally, ECHO and six-minute walk should be repeated at least yearly (59) and a decline in sixminute walk distance may prompt further evaluation for any progression of PH.
Conclusion
In conclusion, autoimmune-diseases-related PH is not uncommon. Early recognition of symptoms and screening of CTD-PAH is important, especially in patients with SSc. The use of intermittent intravenous cyclophosphamide may be useful in patients with SLE who exhibit features of immune-mediated vasculopathy, and there may be a role of immunosuppressant as maintenance regimen. Early initiation of combination therapy of pulmonary vasodilatory agents is beneficial in functional class II patient or above. 
